

Substitute PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/028,944
				Filing Date	December 21, 2001
				First Named Inventor	HORWITZ, David A.
				Group Art Unit	465+ 1654
Examiner Name					
Sheet	1	of	1	Attorney Docket Number	A-67279-5/RFT/RMS/RMK (469443-4)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SL	A1	6,447,765 B1	09-2002	Horwitz	
SL	A2	6,406,696 B1	06-2002	Bluestone	
SL	A3	6,358,506 B1	03-2002	Horwitz	
SL	A4	6,228,359 B1	05-2001	Horwitz	
	A5				
	A6				
	A7				
	A8				
	A9				
	A10				
	A11				

**RECEIVED**  
**MAR 19 2003**  
**TECH CENTER 1600/2900**

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
SL	B1	WO 99/25366 A1	05-1999	Horwitz		
SL	B2	WO 00/66158 A2	11-2000	Horwitz		
	B3					
	B4					
	B5					
	B6					

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					T <sup>6</sup>
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
SL	C1	CHEN W, et al., "T cells specific for a polymorphic segment of CD45 induce graft-versus-host disease with predominant pulmonary vasculitis." J Immunol. 1998 Jul 15;161(2):909-18.			
	C2	EARLY E, and Reen DJ. "Rapid conversion of naive to effector T cell function counteracts diminished primary human newborn T cell responses." Clin Exp Immunol. 1999 Jun;116(3):527-33. (Abstract)			
	C3	GARDERET L, et al., "Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations." Transplantation. 1999 Jan 15;67(1):124-30.			
	C4	HEITGER A, et al. "Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation." Blood. 1997 Jul 15;90(2):850-7.			
	C5	SYKES, M. et al., "In Vitro And In Vivo Analysis Of Bone Marrow-Derived CD3+, CD4-, CD8-, NK1.1+ Cell Lines," Cell Immunol. 129(2):478-93 (1990)			

Examiner Signature	<i>James D. We</i>	Date Considered	5/20/03
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1106700\_1.DOC

5 no persons are required

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

<b>Application Number</b>	10/028,944
<b>Filing Date</b>	December 21, 2001
<b>First Named Inventor</b>	HORWITZ, David A.
<b>Group Art Unit</b>	<del>1654</del> 1654
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	A-67279-5/RFT/RMS/RMK

Sheet	1	of	8
-------	---	----	---

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>James D. He</i>	Date Considered	5/20/03
-----------------------	--------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> Unique citation designation number. <sup>3</sup> See attached forms of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English Language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	2	of	8	Attorney Docket Number	A-67279-5/RFT/RMS/RM
-------	---	----	---	------------------------	----------------------

**Complete if Known**

Application Number	10/028,944
Filing Date	December 21, 2001
First Named Inventor	HORWITZ, David A.
Group Art Unit	1651 1654
Examiner Name	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SL	6.	ANASETTI et al., "Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody", Transplantation 54:844-851 (1992)	
SL	7.	ASAI O, et al., "Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation," Journal of Clinical Investigation 101(9):1835-1842 (1998)	
SL	8.	ASANO M, et al., "Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation." J Exp Med. 1996 Aug 1;184(2):387-96.	
SL	9.	AUCHINCLOSS, Hugh Jr., et al, in Fundamental Immunology 4th Ed., Paul, W.E. (ed.) Lippincot-Raven: Philadelphia, New York; 1999 pp. 1182-1222.	
SL	10.	BARKER et al., "Identification of multiple and distinct CD8+ T cell suppressor activities: dichotomy between infected and uninfected individuals, evolution with progression of disease, and sensitivity to gamma irradiation," J Immunol 156:4476-4483 (1996)	
SL	11.	BETZ, M. and FOX, B.S., "Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines," J Immunol. 1991 Jan 1;146(1):108-13.	
SL	12.	BLAZAR et al., "Both CD4+ and CD8+ T Cells Can Cause Accelerated GVHD Lethality in the Presence of High In Vivo Doses of Exogenous IL10: Role of Interferon Gamma (IFN $\gamma$ ) in GVHD Induction, Blood 88:247 (1996) (abstract)	
SL	13.	BLAZAR et al., "FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation", J. Immunol 153:1836-1846 (1994)	
SL	14.	BLAZAR et al., "Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome", J. Immunol 151:5726-5741 (1993)	
SL	15.	BLAZAR et al., "Recent advances in graft-versus-host disease (GVHD)", Immunol Rev 157:79-90 (1997)	
SL	16.	BONIG H, et al., "Transforming growth factor-beta1 suppresses interleukin-15-mediated interferon-gamma production in human T lymphocytes." Scand J Immunol. 1999 Dec;50(6):612-8.	
SL	17.	BONINI et al., "HSY-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia, Science 276:1719-1724 (1997)	
SL	18.	BORDER et al., "Transforming growth factor-beta in disease: the dark side of tissue repair," J Clin Invest 90:1-7 (1992)	
SL	19.	BOUSSIOTIS et al., "B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance," J Exp Med 178:1753-1763 (1993)	
SL	20.	BOUSSIOTIS, "Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor- $\beta$ -treated alloreactive T cells that do not induce graft-versus-host disease," Blood 97:565-571 (Jan 2001)	
SL	21.	BU CY, R.P. et al., FASEB J. 1995 9:A497 (Abstract)	
SL	22.	CHANDRASEKAR, B., et al., "Dietary calorie restriction inhibits transforming growth factor-beta (TGF- $\beta$ ) expression in murine lupus nephritis", 9th International Congress on Immunology, 848 (1995)	

Examiner Signature	<i>Amund. Lee</i>	Date Considered	5/20/03
--------------------	-------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/028,944		
		Filing Date	December 21, 2001		
		First Named Inventor	HORWITZ, David A.		
		Group Art Unit	4651-1654		
		Examiner Name			
Sheet	3	of	8	Attorney Docket Number	A-67279-5/RFT/RMS/RMK

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SL	23.	CHAVIN et al., "Anti-CD2 mAbs Suppress Cytotoxic Lymphocyte Activity by the Generation of Th2 Suppressor Cells and Receptor Blockade," J Immunol 152:3729-3739 (1994)	
SL	24.	CHONG P. et al. "Inhibition of protein-kinase C in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: effect on spontaneous immunoglobulin production," Autoimmunity, 10:227-231 (1991)	
SL	25.	COSIMI, A.B., et al., "Treatment of acute renal allograft rejection with OKT3 monoclonal antibody," Transplantation. 1981 Dec;32(6):535-9.	
SL	26.	DELGIUDICE, G., et al., "TGF-beta activity is increased in systemic lupus erythematosus (SLE) and progressive systemic sclerosis (PSS)", Arthritis and Rheumatism Vol. 36 (9 Suppl.) p S196(Sept. 1993)	
SL	27.	DOOMS, H. et al., "IL-2 and IL-15 direct the outcome of inappropriate CD4+ T cell stimulation towards apoptosis and anergy respectively," European Cytokine Network, 9(3):169 (1998)	
SL	28.	DUMONT et al., "Distinct Mechanisms of Suppression of Murine T Cell Activation by the Related macrolides FK-506 and Rapamycin", J. Immunol 144:251-258 (1990)	
SL	29.	DUPONT, B., "Immunology of hematopoietic stem cell transplantation: a brief review of its history", Immunol Reviews 157:5-12 (1997)	
SL	30.	FAST, "Generation and characterization of IL-2-activated veto cells", J Immunol 149:1510-1515 (1992)	
SL	31.	FERNANDES, G., et al., "Calorie restriction delays autoimmune murine lupus by differentially modulating oncogenes and TGF- beta-1 expression", 9th International Congress on Immunology., 848 (1995).	
SL	32.	FOWLER et al., "Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice", Blood 84:3540-3549 (1994)	
SL	33.	GAO Q, et al., "CD4+CD25+ cells regulate CD8 cell anergy in neonatal tolerant mice." Transplantation. 1999 Dec 27;68(12):1891-7.	
SL	34.	GOLDMAN et al., "Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion", Ann Intern Med 108:806-814 (1988)	
SL	35.	GRATAMA et al., "Treatment of Acute Graft-Versus-Host Disease With Monoclonal Antibody OKT3. Clinical results and effect on circulating T lymphocytes", Transplantation 38(5):469-474 (1984)	
SL	36.	GRAY et al., "Activated Natural Killer Cells Can Induce Resting B Cells to Produce Immunoglobulin," Arthritis & Rheumatism, 37(9)suppl:S378 (1994)	
SL	37.	GRAY, J. D., et al., "Generation of an Inhibitory Circuit Involving CD8+ T Cells, IL-2, and NK Cell-Derived TGF-β: Contrasting Effects of Anti-CD2 and Anti-CD3", J. Immunol., 160:2248-2254 (1998).	
SL	38.	GRAY, J. D., et al., "The Role of Transforming Growth Factor β in the Generation of Suppression: An Interaction between CD8+ T and NK Cells", J. Exp. Med., 180:1937-1942 (Nov. 1994)	
SL	39.	GRIBBEN et al., "Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool", Blood 97:4887-4893 (1996)	
SL	40.	GROUX, H., et al., "A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis," Nature. 1997 Oct 16;389(6652):737-42.	

Examiner Signature	<i>Ann D. Lee</i>	Date Considered	5/20/03
--------------------	-------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substituted Page 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/028,944		
		Filing Date	December 21, 2001		
		First Named Inventor	HORWITZ, David A.		
		Group Art Unit	1654 1654		
		Examiner Name			
Sheet	4	of	8	Attorney Docket Number	A-67279-5/RFT/RMS/RMK

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SL	41.	HAHN, B.H., Dubois' Lupus Erythematosus, 5th Ed. (1997), pp. 69-76 (D.J. Wallace et al. eds., Williams and Wilkins, Baltimore)	
SL	42.	HALVERSON, et al., "In Vitro Generation of Allospecific Human CD8+ T Cells of Tc1 and Tc2 Phenotype," Blood 90(5):2089-2096 (1997)	
SL	43.	HAN, et al., "A New Type of CD4+ Suppressor T cell Completely Prevents Spontaneous Autoimmune Diabetes and Recurrent Diabetes in Syngeneic Islet-Transplanted NOD Mice," Journal of Autoimmunity, 9:331-339 (1996)	
SL	44.	HERVE et al., "Treatment of Corticosteroid Resistant Acute Graft-Versus-Host Disease by In Vivo Administration of Anti-Interleukin-2 Receptor Monoclonal Antibody (B-B10)," Blood 75(4):1017-1023 (1990)	
SL	45.	HIROHATA et al., "Role of IL-2 in the generation of CD4+ suppressors of human B cell responsiveness," J Immunol 142:3104-3112 (1989)	
SL	46.	HIROKAWA et al., "Human resting B lymphocytes can serve as accessory cells for anti-CD2-induced T cell activation", J. Immunol. 149:1859-1866, 1992	
SL	47.	HIRUMA et al., "Effects of anti-CD3 monoclonal antibody on engraftment of T-cell-depleted bone marrow allografts in mice: host T-cell suppression, growth factors, and space", Blood 79:3050-3058 (1992)	
SL	48.	HORWITZ DA, et al., "Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus." Arthritis Rheum. 1998 May;41(5):838-44.	
SL	49.	HORWITZ, D. A., et al., "The immunoregulatory effects of NK cells: the role of TGF-β and implications for autoimmunity", Immunology Today, Vol. 18(11):538-542 (Nov. 1997).	
SL	50.	HORWITZ, D.A., Dubois' Lupus Erythematosus, 5th Ed. (1997), pp. 155-194 (D.J. Wallace et al. eds., Williams and Wilkins, Baltimore)	
SL	51.	HUGGINS, M. L., et al., "Modulation of the Autoimmune Response in Lupus Mice by Oral Administration of Attenuated Salmonella typhimurium Expressing the IL-2 and TGF-β Genes", Annals of New York Acad. of Sciences, Vol. 815:499-502 (1997)	
SL	52.	JACKSON AL, et al., "Restricted expression of p55 interleukin 2 receptor (CD25) on normal T cells." Clin Immunol Immunopathol. 1990 Jan;54(1):126-33.	
SL	53.	JONULEIT, H., et al., "Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells," J Exp Med. 2000 Nov 6;192(9):1213-22.	
SL	54.	KANEGANE H, et al., "A novel subpopulation of CD45RA+ CD4+ T cells expressing IL-2 receptor alpha-chain (CD25) and having a functionally transitional nature into memory cells." Int Immunol. 1991 Dec;3(12):1349-56.	
SL	55.	KINTER et al., "Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to simulate virus expression", Proc. Natl. Acad. Sci. USA 92:10985-10989 (1995)	
SL	56.	KIRK, A.D., et al., "CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates," Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8789-94.	
SL	57.	KLINMAN DM, et al., "Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus." Arthritis Rheum. 1991 Nov;34(11):1404-10.	
SL	58.	KOH et al., "Adoptive cellular immunotherapy: NK cells and bone marrow transplantation," Histol Histopathol 15:1201-1210 (2000)	

Examiner Signature	<i>Man D. Lee</i>	Date Considered	5/20/03
--------------------	-------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/028,944		
		Filing Date	December 21, 2001		
		First Named Inventor	HORWITZ, David A.		
		Group Art Unit	4654 1654		
		Examiner Name			
Sheet	5	of	8	Attorney Docket Number	A-67279-5/RFT/RMS/RMK

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SL	59.	KOIDE, J. and ENGLEMAN, E.G., "Differences in surface phenotype and mechanism of action between alloantigen-specific CD8+ cytotoxic and suppressor T cell clones," J Immunol. 1990 Jan 1;144(1):32-40.	
SL	60.	KRENGER et al., "Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens," Transplantation 58:1251-1257 (1994)	
SL	61.	KRENGER et al., "Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease," J Immunol 153:585-593 (1995)	
SL	62.	LANCASTER, F., et al., "Anti-idiotypic T cells suppress rejection of renal allografts in rats," Nature. 1985 May 23-29;315(6017):336-7.	
SL	63.	LANGREHR, J.M., et al., "Evidence that nitric oxide production by in vivo allosensitized cells inhibits the development of allospecific CTL," Transplantation. 1992 Mar;53(3):632-40.	
SL	64.	LARSEN, C.P., et al., "Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways," Nature. 1996 May 30;381(6581):434-8.	
SL	65.	LINKER-ISRAELI M, et al., "CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis," Arthritis Rheum. 1990 Aug;33(8):1216-25.	
SL	66.	LUCAS et al., "The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation," Blood 87:2594-2603 (1996)	
SL	67.	MARTIN et al., "Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts," Blood 66:664-672 (1985)	
SL	68.	MARTIN et al., "Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease," Bone Marrow Transplant 3:437-444 (1989)	
SL	69.	MARTIN, "Overview of Marrow Transplantation Immunology", in Bone Marrow Transplantation (eds. Forman et al.) pp. 16-21, Boston, Blackwell Scientific Publications (1994)	
SL	70.	MARTIN, P.J. et al., "Treatment of Acute Graft-Versus-Host Disease with Anti-CD3 Monoclonal Antibodies," Am Jour Kidney Disease 11(2):149-152 (1988)	
SL	71.	MASSAGUE, "Receptors for the TGF-beta family", Cell 69:1067-1070 (1992)	
SL	72.	MASSAGUE J., "The transforming growth factor-beta family." Annu Rev Cell Biol. 1990;6:597-641.	
SL	73.	MIZUOCHI, T., et al., "Both L3T4+ and Lyt-2+ helper T cells initiate cytotoxic T lymphocyte responses against allogeneic major histocompatibility antigens but not against trinitrophenyl-modified self," J Exp Med. 1985 Aug 1;162(2):427-43.	
SL	74.	MORRIS, "Prevention and treatment of allograft rejection in vivo by rapamycin: molecular and cellular mechanisms of action", Ann NY Acad Sci 685:68-72 (1993)	
SL	75.	MURPHY et al., "The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation," Immunol Rev 157:167-176 (1997)	
SL	76.	MYSLIWIETZ J and Thierfelder S., "Antilymphocytic antibodies and marrow transplantation. XII. Suppression of graft-versus-host disease by T-cell-modulating and depleting antimouse CD3 antibody is most effective when preinjected in the marrow recipient." Blood. 1992 Nov 15;80(10):2661-7 (Abstract)	
SL	77.	OHTSUKA, K., et al., "Decreased Production of TGF-beta by Lymphocytes from Patients with Systemic Lupus Erythematosus", J. Immunol. 160:2539-2545 (1998).	

Examiner Signature	<i>Andrew D. Lee</i>	Date Considered	5/20/03
--------------------	----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

AUG 22 2002

TECH CENTER 1500/2900

Please type a plus sign (+) inside this box ☐



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. PTO 0681-003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED  
AUG 2 2002  
TECH CENTER 1600/2900

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/028,944		
		Filing Date	December 21, 2001		
		First Named Inventor	HORWITZ, David A.		
		Group Art Unit	4651 1654		
Examiner Name					
Sheet	6	of	8	Attorney Docket Number	A-67279-5/RFT/RMS/RMK

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SL	78.	OSWALD, et al., "IL-10 Synergizes with IL-4 and Transforming Growth Factor-Beta to Inhibit macrophage Cytotoxic Activity," J Immunology 148(11):3578-3582 (1992)	
SL	79.	PAPIERNIK M, et al., "T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity." J Immunol. 1997 May 15;158(10):4642-53.	
SL	80.	PATTERSON et al., "Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation", Br J Haematol 63:221-230 (1986)	
SL	81.	PAWELEC, et al., "Cytokine Modulation of TH1/TH2 Phenotype Differentiation in Directly Alloresponsive CD4+ Human T Cells," Transplantation, 62(8):1095-1101 (October 1996).	
SL	82.	PEARCE, N.W., et al., "Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. V. Dependence of CD4+ suppressor cells on the presence of alloantigen and cytokines, including interleukin 2," Transplantation. 1993 Feb;55(2):374-80.	
SL	83.	PESCOVITZ, M.D., et al., "Effect of class II antigen matching on renal allograft survival in miniature swine," J Exp Med. 1984 Nov 1;160(5):1495-508. QIN, L., et al., "Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-beta 1," Ann Surg. 1994 Oct;220(4):508-18; discussion 518-9.	
SL	84.	POWRIE F, et al., "A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells." J Exp Med. 1996 Jun 1;183(6):2669-74.	
SL	85.	QIN, L., et al., "Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-beta 1," Ann Surg. 1994 Oct;220(4):508-18; discussion 518-9	
SL	86.	QIN, L., et al., "Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival," J Immunol. 1996 Mar 15;156(6):2316-23.	
SL	87.	RAJU, G.P., et al., "Prolongation of cardiac allograft survival with transforming growth factor-beta 1 in rats," Transplantation. 1994 Aug 15;58(3):392-6.	
SL	88.	RAMSDELL, F. and FOWLKES, B.J., "Maintenance of in vivo tolerance by persistence of antigen," Science. 1992 Aug 21;257(5073):1130-4.	
SL	89.	READ S, et al., "Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation." J Exp Med. 2000 Jul 17;192(2):295-302.	
SL	90.	ROCHA, B., et al., "Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen," J Exp Med. 1993 May 1;177(5):1517-21.	
SL	91.	RODT, H., "Anti-lymphocytic antibodies and marrow transplantation. 3. Effect of heterologous anti-brain antibodies on acute secondary disease in mice", Eur. J. Immunol 4:25-29 (1974)	
SL	92.	ROOK et al., "Effects of Transforming Growth Factor beta on the Functions of Natural Killer Cells: Depressed Cytolytic Activity and Blunting of Interferon Responsiveness," J Immunology 136(10):3916-3920 (1986)	
SL	93.	ROSER, B.J., "Cellular mechanisms in neonatal and adult tolerance," Immunol Rev. 1989 Feb;107:179-202.	
SL	94.	SAKAGUCHI, S., et al., "Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases," J Immunol. 1995 Aug 1;155(3):1151-64.	
SL	95.	SAKAGUCHI S, et al., "Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease." J Exp Med. 1985 Jan 1;161(1):72-87.	

Examiner Signature	<i>Norm D. Lee</i>	Date Considered	5/20/03
--------------------	--------------------	-----------------	---------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1087601\_1.DOC

Please type a plus sign (+) inside this box ☐



PTO/SB/8B (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/028,944
		Filing Date	December 21, 2001
		First Named Inventor	HORWITZ, David A.
		Group Art Unit	1651 1654
		Examiner Name	
Sheet	7	of	8
		Attorney Docket Number	A-67279-5/RFT/RMS/RMK

RECEIVED  
AUG 22 2002  
TECHNICAL CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SL	96.	SEDDON, B. and MASON, D., "The third function of the thymus," Immunol Today. 2000 Feb;21(2):95-9.	
SL	97.	SHEVACH, E.M., "Regulatory T cells in autoimmunity," Annu Rev Immunol. 2000;18:423-49.	
SL	98.	SHIVAKUMAR S, et al., "T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis." J Immunol. 1989 Jul 1;143(1):103-12.	
SL	99.	SINGER, A., et al., "Self recognition in allogeneic radiation bone marrow chimeras. A radiation-resistant host element dictates the self specificity and immune response gene phenotype of T-helper cells," J Exp Med. 1981 May 1;153(5):1286-301.	
SL	100.	SNIJDEWINT, F.G., et al., "Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes," J Immunol. 1993 Jun 15;150(12):5321-9.	
SL	101.	SPORN et al., "Some recent advances in the chemistry and biology of transforming growth factor-beta," J Cell Biol 105:1039-1045 (1987)	
SL	102.	STARZL, T.E., et al., "Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation," Transplantation. 1993 Jun;55(6):1272-7.	
SL	103.	STORB et al., "Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia", Blood 80:560-561 (1992)	
SL	104.	STRAND, V., "Approaches to the management of systemic lupus erythematosus," Current Opinion in Rheumatology, 9:410-420 (1997)	
SL	105.	SULLIVAN et al., "Chronic Graft-Versus-Host Disease and Other Late Complications of Bone Marrow Transplantation", Semin Hematol 28:250-259 (1992)	
SL	106.	SURI-PAYER E, et al., "CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells." J Immunol. 1998 Feb 1;160(3):1212-8.	
SL	107.	SURI-PAYER E, et al., "Post-thymectomy autoimmune gastritis: fine specificity and pathogenicity of anti-H/K ATPase-reactive T cells." Eur J Immunol. 1999 Feb;29(2):669-77.	
SL	108.	TAAMS, L.S., et al., "Anergic T cells actively suppress T cell responses via the antigen-presenting cell," Eur J Immunol. 1998 Sep;28(9):2902-12.	
SL	109.	TAKAHASHI T, et al., "Human CD8+ lymphocytes stimulated in the absence of CD4+ cells enhance IgG production by antibody-secreting B cells." Clin Immunol Immunopathol. 1991 Mar;58(3):352-65.	
SL	110.	TAKAHASHI T, et al., "Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state." Int Immunol. 1998 Dec;10(12):1969-80.	
SL	111.	TAYLOR, "Antigen specific suppressor T cells respond to cytokines released by T cells", Advances Exp Med Biol 319:125-135 (1992)	
SL	112.	THORNTON AM and Shevach EM. "CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production." J Exp Med. 1998 Jul 20;188(2):287-96.	
SL	113.	THORNTON AM and Shevach EM. "Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific." J Immunol. 2000 Jan 1;164(1):183-90.	

Examiner Signature	<i>Man D. Lee</i>	Date Considered	5/20/03
--------------------	-------------------	-----------------	---------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box ☐



Approved for use through 10/31/2002 OMB 0651-0081  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED  
FEB 22 2002  
TECHNICAL CENTER 1600/2900

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/028,944
		Filing Date	December 21, 2001
		First Named Inventor	HORWITZ, David A.
		Group Art Unit	4651 1654
		Examiner Name	
Sheet	8	of	8
		Attorney Docket Number	A-67279-5/RFT/RMS/RMK

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SL	114.	TOMITA, Y., et al., "Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance?" J Immunol. 1990 Jan 15;144(2):463-73.	
SL	115.	VALLERA et al., "Bone marrow transplantation across major histocompatibility barriers in mice. Effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus complement or antibody alone", Transplantation 31:218-222 (1981)	
SL	116.	VENDETTI, S., et al., "Anergic T cells inhibit the antigen-presenting function of dendritic cells," J Immunol. 2000 Aug 1;165(3):1175-81.	
SL	117.	VERBANAC, K.M., et al., "A role for transforming growth factor-beta in the veto mechanism in transplant tolerance," Transplantation. 1994 Mar 27;57(6):893-900.	
SL	118.	VIA et al., "Critical Role of interleukin-2 in the development of acute graft-versus-host disease", International Immunol 5:565-572 (1993)	
SL	119.	WAHL SM. "Transforming growth factor beta: the good, the bad, and the ugly." J Exp Med. 1994 Nov 1;180(5):1587-90.	
SL	120.	WEINER HL, et al., "Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens." Annu Rev Immunol. 1994;12:809-37	
SL	121.	WEKERLE, T., et al., "Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance," Transplantation. 1999 Nov 15;68(9):1348-55.	
SL	122.	WILSON, D.B., "Idiotypic regulation of T cells in graft-versus-host disease and autoimmunity," Immunol Rev. 1989 Feb;107:159-77.	
SL	123.	ZEHAVER-WILLNER et al., "The Mitogenic Activity of Staphylococcal Enterotoxin B (SEB): A Monovalent T Cell Mitogen That Stimulates Cytolytic T Lymphocytes but Cannot Mediate Their Lytic Interaction," Journal of Immunology 137(8):2682-2687 (Oct 1986)	
SL	124.	ZELLER et al., "Induction of CD4+ T Cell Alloantigen-Specific Hyporesponsiveness by IL-10 and TGF-β1," Journal of Immunology 163:3684-3691 (1999)	
SL	125.	ZELLER, et al., "Ex vivo IL10 and TGF-Beta Act Synergistically to Induce CD4+ Alloantigen-Specific Tolerance Resulting in Diminished Graft-Versus-Host Disease in Vivo," FASEB Journal (March 12, 1999) 12(4)part 1, A614. Meeting Info: Annual Meeting of the Professional Research Scientists for Experimental Biology. April 17-21 1999.	
SL	126.	ZHENG, X.X., et al., "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation," J Immunol. 1995 May 15;154(10):5590-600.	

Examiner Signature	<i>Ann D Lee</i>	Date Considered	5/20/03
--------------------	------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.